Novel Compounds

NeuMedics compounds are patented  and tested to confirm:

Neumedics compounds are patented and tested to confirm:

NeuMedics central hypothesis is that increased inflammatory CC chemokine’s in the diabetic retina alter the blood-retinal barrier through the recruitment of immune cells. Despite the use of molecular therapeutics targeting vascular endothelial growth factor (VEGF), the majority of patients do not recover good, functional vision, and show residual edema, necessitating repeated intravitreal injections. The scientific gap is due to the present inability to completely block all the inflammatory mediators implicated in the pathogenesis of DME.

Evidence suggests that diabetic retinopathy is an inflammatory disease. The precise mechanism by which the chemokine’s and leukocytes initiate the inflammatory cascade and finally damages this barrier is not clear. CC chemokine’s (CCL2, 5 and 7) are significantly up regulated in the retinas of diabetic animals. Also, there is increased trafficking of monocytes into the retina along with activation of retinal microglia in diabetes. The NeuMedics approach is innovative as it addresses a novel mechanism of stabilizing the initial step of leukocyte-endothelial interaction, the critical upstream bottleneck for diabetic macular edema.